Methylated RASSF1a Is the first specific DNA marker for minimal residual disease testing in neuroblastoma

Janine Stutterheim, Fatima Ait Ichou, Emmy Den Ouden, Rogier Versteeg, Huib N. Caron, Godelieve A.M. Tytgat, C. Ellen Van Der Schoot

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

32 Citaten (Scopus)


Purpose: PCR-based detection of minimal residual disease (MRD) in neuroblastoma (NB) is presently based on NB-specific transcripts. However, the expression of these targets varies between patients and upon treatment, and only PHOX2B is truly specific. RASSF1a is methylated (RASSF1a M) in NB, and we investigated whether it can serve as a specific and stable DNA MRD marker. Patients and Methods: The RASSF1a M-specific quantitative real-time PCR was tested on control bone marrow (BM; n=50), on 71 NB tumors, and on 159 clinical BM samples at diagnosis and at follow-up of 77 patients. Results were compared with a panel of RNA markers and correlated with prognosis. Results: RASSF1a M was present in all stage 4 and 4s tumors (n = 50) and in 86% stages 1 to 3 tumors (n = 21). The level of methylation in stage 4 NB was correlated with overall survival (P = 0.02). RASSF1a M-PCR was highly specific (only 1 amplification in 50 control samples tested in triplicate) and had a similar sensitivity as the RNA-based PCRs, as shown on clinical samples. Moreover, RASSF1a M enabled accurate quantification without need for the original tumor. Conclusions: RASSF1a M is a novel, highly specific DNA marker for MRD detection in NB, equal to PHOX2B in specificity and sensitivity, and better suitable for MRD quantification. We propose to include RASSF1a M in further prospective MRD studies in NB alongside RNA MRD markers. In addition, this assay might also be applicable for detection of circulating tumor cells in patients with other cancers with RASSF1a Msuch as breast or lung cancer.

Originele taal-2Engels
Pagina's (van-tot)808-814
Aantal pagina's7
TijdschriftClinical Cancer Research
Nummer van het tijdschrift3
StatusGepubliceerd - 1 feb. 2012
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Methylated RASSF1a Is the first specific DNA marker for minimal residual disease testing in neuroblastoma'. Samen vormen ze een unieke vingerafdruk.

Citeer dit